CEO of TSX.V listed Fura Gems, Dev Shetty, talks about how the company ethically sources their gems, the future of Fura Gems and more on Nasdaq TV.
About Fura Gems
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180703005456/en/
Fura Gems Inc. is a gemstone mining and marketing company which is engaged in the mining, exploration and acquisition of gemstone licences. Fura’s headquarters are located in Toronto, Canada and its administrative headquarters are located in the Almas Tower, Dubai. Fura is listed on the TSX Venture Exchange under the ticker symbol “FURA”.
Fura is engaged in the exploration of resource properties in Colombia and owns a 76% interest in the Coscuez emerald mine in Boyacá, Colombia. Fura is also involved in the exploration and mining of rubies in Mozambique through its 80% effective interest in the four ruby licences (4392, 3868, 3869 and 6811).
Fura Gems Inc.
Dev Shetty - President & Chief Executive Officer
Tel: +971 (0) 4 240 8760
Vikram Pathak – Investor Relations
Jos Simson / Barney Hayward
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
FL-MLB22.9.2018 00:15 | pressemeddelelse
American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)
NY-BCW/PALLADINO21.9.2018 19:45 | pressemeddelelse
Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice
HEIDELBERG-ENGINEERING21.9.2018 18:43 | pressemeddelelse
Heidelberg Engineering Announces the CE-Marking of ANTERION
JEDOX21.9.2018 17:48 | pressemeddelelse
Florian Winterstein Becomes New CEO of Jedox
AVINOR21.9.2018 16:39 | pressemeddelelse
Avinor to Test Autonomous Snowploughs at Oslo Airport This Winter
MA-TAKEDA-PHARMACEUTICAL21.9.2018 15:32 | pressemeddelelse
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum